Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Rallybio Corp (RLYB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: RLYB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -74.54% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 27.24M USD | Price to earnings Ratio - | 1Y Target Price 8.25 |
Price to earnings Ratio - | 1Y Target Price 8.25 | ||
Volume (30-day avg) 47575 | Beta -1.45 | 52 Weeks Range 0.60 - 3.46 | Updated Date 04/1/2025 |
52 Weeks Range 0.60 - 3.46 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.36 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-03-13 | When - | Estimate -0.2967 | Actual -0.25 |
Profitability
Profit Margin - | Operating Margin (TTM) -30547.37% |
Management Effectiveness
Return on Assets (TTM) -38.91% | Return on Equity (TTM) -68.85% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -38121921 | Price to Sales(TTM) 42.82 |
Enterprise Value -38121921 | Price to Sales(TTM) 42.82 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.41 | Shares Outstanding 41612000 | Shares Floating 19732013 |
Shares Outstanding 41612000 | Shares Floating 19732013 | ||
Percent Insiders 4.04 | Percent Institutions 77.11 |
Analyst Ratings
Rating 4.6 | Target Price 8.25 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Rallybio Corp
Company Overview
History and Background
Rallybio Corp is a clinical-stage biotechnology company focused on identifying and developing therapies for patients with severe and rare diseases. Founded in 2018, the company went public in 2021 and is headquartered in New Haven, Connecticut.
Core Business Areas
- Hematology: Developing therapies for hematologic disorders, including complement-mediated diseases and thrombocytopenia.
- Rare Diseases: Focuses on developing therapies for rare diseases with unmet medical needs.
Leadership and Structure
The leadership team includes Martin Mackay, Ph.D., Co-Founder and CEO. The company's structure includes research and development, clinical operations, and business development functions.
Top Products and Market Share
Key Offerings
- RLYB211: RLYB211 is a monoclonal antibody inhibiting complement component C5, being developed for the treatment of complement-mediated diseases, with initial focus on paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG). There is no market share data yet, as it is in clinical development. Competitors include Alexion Pharmaceuticals (acquired by AstraZeneca) with Soliris and Ultomiris, and Apellis Pharmaceuticals with Empaveli.
- RLYB212: RLYB212 is a subcutaneous anti-C5a monoclonal antibody to control complement activation. There is no market share data yet, as it is in clinical development. Competitors include InflaRx and others developing C5a inhibitors.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, regulatory hurdles, and competition. The rare disease market is growing due to increased awareness, orphan drug designations, and advancements in genetic testing.
Positioning
Rallybio is positioned as a clinical-stage company focused on developing targeted therapies for rare and severe diseases with high unmet medical needs. Their competitive advantage lies in their experienced leadership team and focus on complement-mediated diseases.
Total Addressable Market (TAM)
The total addressable market for rare disease therapies is estimated to be billions of dollars. Rallybio is targeting specific segments of this market, focusing on complement-mediated diseases and hematologic disorders, allowing for a more focused approach to capturing market share.
Upturn SWOT Analysis
Strengths
- Experienced leadership team
- Focus on complement-mediated diseases
- Strong intellectual property portfolio
- Multiple clinical-stage programs
Weaknesses
- Limited operating history
- Dependence on clinical trial success
- High cash burn rate
- Reliance on third-party manufacturers
Opportunities
- Expansion into new rare disease indications
- Potential for strategic partnerships
- Accelerated regulatory pathways for rare disease therapies
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory setbacks
- Difficulty in raising capital
Competitors and Market Share
Key Competitors
- ALXN
- APLS
Competitive Landscape
Rallybio faces competition from established pharmaceutical companies with approved therapies for complement-mediated diseases. Their competitive advantage lies in novel therapies and focused indication.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Rallybio's historical growth is defined by its progress in clinical trials and expansion of its pipeline.
Future Projections: Future growth is dependent on clinical trial successes and regulatory approvals. Analyst estimates vary depending on the prospects of their pipeline.
Recent Initiatives: Recent initiatives include advancing RLYB211 and RLYB212 through clinical development.
Summary
Rallybio is a clinical-stage biotech firm aiming to treat rare diseases, especially those mediated by the complement system. Its strength lies in its focused approach and experienced team, but it is vulnerable to clinical trial risks and cash burn. Future success hinges on positive trial outcomes and regulatory approvals. The company is poised for growth should their products succeed, but faces considerable challenges in the competitive pharmaceutical landscape.
Similar Companies
- ALXN
- APLS
- GBT
- VCYT
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biotechnology industry is inherently risky, and future performance is not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rallybio Corp
Exchange NASDAQ | Headquaters New Haven, CT, United States | ||
IPO Launch date 2021-07-29 | Co-Founder, President, CEO & Director Dr. Stephen Uden M.B, M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 25 | Website https://www.rallybio.com |
Full time employees 25 | Website https://www.rallybio.com | ||
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.